Drug Interaction Report

Treatment with C5 inhibitors like crovalimab and ravulizumab may cause immune system reactions known as type III hypersensitivity reactions. If you are switching from ravulizumab to crovalimab, or vice versa, you might experience these reactions. In addition, if you are switching from ravulizumab to crovalimab, your doctor will monitor you closely for 30 days after the switch to watch for signs of type III hypersensitivity reactions. They may also delay starting the new treatment to reduce this risk. Seek medical attention if you develop symptoms such as joint pain, muscle or bone pain, skin rash, itching, headache, kidney issues, numbness or tingling in your hands and feet, fever, fatigue, or stomach problems. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

The recommended maximum number of medicines in the 'immunosuppressants for PNH' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'immunosuppressants for PNH' category:

• crovalimab
• ravulizumab

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.